• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

降低血压对透析患者心血管事件及死亡率的影响:一项随机对照试验的系统评价与荟萃分析

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.

作者信息

Heerspink Hiddo J Lambers, Ninomiya Toshiharu, Zoungas Sophia, de Zeeuw Dick, Grobbee Diederick E, Jardine Meg J, Gallagher Martin, Roberts Matthew A, Cass Alan, Neal Bruce, Perkovic Vlado

机构信息

George Institute for International Health, University of Sydney, Sydney, Australia.

出版信息

Lancet. 2009 Mar 21;373(9668):1009-15. doi: 10.1016/S0140-6736(09)60212-9. Epub 2009 Feb 25.

DOI:10.1016/S0140-6736(09)60212-9
PMID:19249092
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2659734/
Abstract

BACKGROUND

Patients undergoing dialysis have a substantially increased risk of cardiovascular mortality and morbidity. Although several trials have shown the cardiovascular benefits of lowering blood pressure in the general population, there is uncertainty about the efficacy and tolerability of reducing blood pressure in patients on dialysis. We did a systematic review and meta-analysis to assess the effect of blood pressure lowering in patients on dialysis.

METHODS

We systematically searched Medline, Embase, and the Cochrane Library database for trials reported between 1950 and November, 2008, without language restriction. We extracted a standardised dataset from randomised controlled trials of blood pressure lowering in patients on dialysis that reported cardiovascular outcomes. Meta-analysis was done with a random effects model.

FINDINGS

We identified eight relevant trials, which provided data for 1679 patients and 495 cardiovascular events. Weighted mean systolic blood pressure was 4.5 mm Hg lower and diastolic blood pressure 2.3 mm Hg lower in actively treated patients than in controls. Blood pressure lowering treatment was associated with lower risks of cardiovascular events (RR 0.71, 95% CI 0.55-0.92; p=0.009), all-cause mortality (RR 0.80, 0.66-0.96; p=0.014), and cardiovascular mortality (RR 0.71, 0.50-0.99; p=0.044) than control regimens. The effects seem to be consistent across a range of patient groups included in the studies.

INTERPRETATION

Treatment with agents that lower blood pressure should routinely be considered for individuals undergoing dialysis to reduce the very high cardiovascular morbidity and mortality rate in this population.

摘要

背景

接受透析的患者心血管疾病死亡率和发病率大幅增加。尽管多项试验已表明在普通人群中降低血压对心血管有益,但对于透析患者降低血压的疗效和耐受性仍存在不确定性。我们进行了一项系统评价和荟萃分析,以评估透析患者降低血压的效果。

方法

我们系统检索了Medline、Embase和Cochrane图书馆数据库,以查找1950年至2008年11月期间报道的试验,无语言限制。我们从透析患者降低血压的随机对照试验中提取了标准化数据集,这些试验报告了心血管结局。采用随机效应模型进行荟萃分析。

结果

我们确定了八项相关试验,这些试验提供了1679例患者和495例心血管事件的数据。积极治疗的患者加权平均收缩压比对照组低4.5 mmHg,舒张压低2.3 mmHg。与对照方案相比,降低血压治疗与心血管事件风险降低(RR 0.71,95%CI 0.55-0.92;p=0.009)、全因死亡率降低(RR 0.80,0.66-0.96;p=0.014)和心血管死亡率降低(RR 0.71,0.50-0.99;p=0.044)相关。在纳入研究的一系列患者组中,这些效应似乎是一致的。

解读

对于接受透析的个体,应常规考虑使用降低血压的药物进行治疗,以降低该人群非常高的心血管发病率和死亡率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/4028590344ef/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/db00040217a0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/f5b1ec026f7f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/660b9fd76677/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/4028590344ef/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/db00040217a0/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/f5b1ec026f7f/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/660b9fd76677/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cec/2659734/4028590344ef/gr4.jpg

相似文献

1
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.降低血压对透析患者心血管事件及死亡率的影响:一项随机对照试验的系统评价与荟萃分析
Lancet. 2009 Mar 21;373(9668):1009-15. doi: 10.1016/S0140-6736(09)60212-9. Epub 2009 Feb 25.
2
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.减少或无麸质饮食对心血管疾病一级预防的影响。
Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2.
3
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
4
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
5
Pharmacotherapy for hypertension in adults aged 18 to 59 years.18至59岁成年人高血压的药物治疗
Cochrane Database Syst Rev. 2017 Aug 16;8(8):CD008276. doi: 10.1002/14651858.CD008276.pub2.
6
Blood pressure lowering efficacy of renin inhibitors for primary hypertension.肾素抑制剂对原发性高血压的降压疗效。
Cochrane Database Syst Rev. 2017 Apr 5;4(4):CD007066. doi: 10.1002/14651858.CD007066.pub3.
7
Beta-blockers for hypertension.用于治疗高血压的β受体阻滞剂。
Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5.
8
Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases.用于预防动脉粥样硬化性心血管疾病的固定剂量联合疗法。
Cochrane Database Syst Rev. 2017 Mar 6;3(3):CD009868. doi: 10.1002/14651858.CD009868.pub3.
9
Pharmacotherapy for hypertension-induced left ventricular hypertrophy.高血压性左心室肥厚的药物治疗。
Cochrane Database Syst Rev. 2021 Oct 10;10(10):CD012039. doi: 10.1002/14651858.CD012039.pub3.
10
Calcium supplementation for prevention of primary hypertension.钙补充预防原发性高血压。
Cochrane Database Syst Rev. 2021 Aug 10;8(8):CD010037. doi: 10.1002/14651858.CD010037.pub3.

引用本文的文献

1
Efficacy and safety of sacubitril-valsartan in Maintenance Hemodialysis patients with hypertension:A retrospective study.沙库巴曲缬沙坦治疗维持性血液透析高血压患者的疗效及安全性:一项回顾性研究
PLoS One. 2025 Sep 4;20(9):e0330038. doi: 10.1371/journal.pone.0330038. eCollection 2025.
2
Combined blood pressure and pulse rate as a new risk marker for mortality in hemodialysis patients.血压与脉搏率联合作为血液透析患者死亡的新风险标志物。
Hypertens Res. 2025 Sep 1. doi: 10.1038/s41440-025-02301-0.
3
Interpretability of Home Blood Pressure Measurements in Haemodialysis A Post Hoc Analysis of a Randomised Cross-Over Study.

本文引用的文献

1
Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial.高血压血液透析患者干体重减轻(DRIP):一项随机对照试验。
Hypertension. 2009 Mar;53(3):500-7. doi: 10.1161/HYPERTENSIONAHA.108.125674. Epub 2009 Jan 19.
2
Blood pressure and mortality risk on peritoneal dialysis.腹膜透析时的血压与死亡风险
Am J Kidney Dis. 2009 Jan;53(1):70-8. doi: 10.1053/j.ajkd.2008.08.030. Epub 2008 Nov 22.
3
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial.
血液透析中家庭血压测量的可解释性:一项随机交叉研究的事后分析
Nephrology (Carlton). 2025 Sep;30(9):e70112. doi: 10.1111/nep.70112.
4
Should We Use Renin-Angiotensin-System Inhibitors As a First-Line Therapy for the Management of Hypertension in Patients Receiving Hemodialysis?我们是否应该将肾素-血管紧张素系统抑制剂作为接受血液透析患者高血压管理的一线治疗方法?
Am J Cardiovasc Drugs. 2025 Aug 7. doi: 10.1007/s40256-025-00756-7.
5
Systematic review and meta-analysis of cardiovascular event risk prediction models in maintenance hemodialysis patients.维持性血液透析患者心血管事件风险预测模型的系统评价与荟萃分析
Sci Rep. 2025 Jul 1;15(1):21807. doi: 10.1038/s41598-025-07586-2.
6
Volume Assessment in Patients Undergoing Long-Term Dialysis.长期透析患者的容量评估
J Am Soc Nephrol. 2025 Jun 1;36(6):1184-1196. doi: 10.1681/ASN.0000000724. Epub 2025 Apr 7.
7
I Brazilian guideline on hypertension in dialysis of the Brazilian Society of Nephrology.我是巴西肾脏病学会巴西透析高血压指南。 (此译文逻辑较怪,原英文表述不太完整准确,可能正确表述是:我是巴西肾脏病学会发布的巴西透析高血压指南 ) 按现有英文直接翻译就是这样,供你参考。
J Bras Nefrol. 2025 Jan-Mar;47(1):e20240033. doi: 10.1590/2175-8239-JBN-2024-0033en.
8
Low dialysate sodium levels for chronic haemodialysis.慢性血液透析中低透析液钠水平。
Cochrane Database Syst Rev. 2024 Nov 5;11(11):CD011204. doi: 10.1002/14651858.CD011204.pub3.
9
Assessment and management of emergencies during haemodialysis.血液透析期间紧急情况的评估与处理
J Nephrol. 2025 Mar;38(2):423-433. doi: 10.1007/s40620-024-02124-1. Epub 2024 Oct 30.
10
Impact of Angiotensin Receptor Blockers (ARB) versus Other Antihypertensive Medication on Blood Pressure in Patients on Dialysis: A Meta-Analysis.血管紧张素受体阻滞剂(ARB)与其他抗高血压药物对透析患者血压的影响:一项荟萃分析。
Indian J Nephrol. 2024 Sep-Oct;34(5):431-441. doi: 10.25259/ijn_365_23. Epub 2024 Jul 8.
血管紧张素受体阻滞剂对接受血液透析患者心血管事件的影响:一项开放标签随机对照试验。
Am J Kidney Dis. 2008 Sep;52(3):501-6. doi: 10.1053/j.ajkd.2008.04.031. Epub 2008 Jul 24.
4
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.氨氯地平对高血压血液透析患者心血管事件的影响。
Nephrol Dial Transplant. 2008 Nov;23(11):3605-12. doi: 10.1093/ndt/gfn304. Epub 2008 May 29.
5
Excerpts from the United States Renal Data System 2007 annual data report.美国肾脏数据系统2007年年报摘录。
Am J Kidney Dis. 2008 Jan;51(1 Suppl 1):S1-320. doi: 10.1053/j.ajkd.2007.11.001.
6
Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study.慢性肾脏病、心血管事件以及培哚普利降压治疗的效果:来自培哚普利预防复发性卒中研究(PROGRESS研究)的数据
J Am Soc Nephrol. 2007 Oct;18(10):2766-72. doi: 10.1681/ASN.2007020256. Epub 2007 Sep 5.
7
Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients.司维拉姆和钙基磷酸盐结合剂对血液透析患者死亡率的影响。
Kidney Int. 2007 Nov;72(9):1130-7. doi: 10.1038/sj.ki.5002466. Epub 2007 Aug 29.
8
Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system.抑制肾素-血管紧张素系统药物的血压依赖性及非依赖性作用
J Hypertens. 2007 May;25(5):951-8. doi: 10.1097/HJH.0b013e3280bad9b4.
9
Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.尿毒症性高同型半胱氨酸血症:叶酸治疗预防心血管事件的一项随机试验。
Hemodial Int. 2007 Apr;11(2):210-6. doi: 10.1111/j.1542-4758.2007.00171.x.
10
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis.接受促红细胞生成素治疗的慢性肾病贫血患者的死亡率及目标血红蛋白浓度:一项荟萃分析。
Lancet. 2007 Feb 3;369(9559):381-8. doi: 10.1016/S0140-6736(07)60194-9.